Randomized phase 1 study of the phosphatidylinositol 3-kinase delta inhibitor idelalisib in patients with allergic rhinitis

摘要

Background: Phosphatidylinositol 3-kinase p110 delta isoform (PI3K p110 delta) activity is essential for mast cell activation, suggesting that inhibition of PI3K p110 delta might be useful in treating allergic diseases.